Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

233.87 +4.30 (+1.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Biogen's New Alzheimer's Drug Will Cost $56,000 Per Year
Biogen set the list price for Aduhelm, its newly approved treatment, and is collaborating with CVS to improve screening for the disease. 
Via The Motley Fool
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
Biogen CEO Michel Vounatsos Talks Alzheimer's Treatment Approval
Biogen Inc (NASDAQ: BIIB) CEO Michel Vounatsos appeared Monday on CNBC's "Power Lunch" to discuss the company's FDA approval announcement. What Happened:... 
Via Benzinga
Exposures Product Safety
Biogen And Norweigan Cruise Line Lead The SPY In A Mixed Day Of Trading
Major U.S. indices had a mixed day of trading Monday as investors continue to weigh better-than-expected May unemployment rate numbers fr... 
Via Benzinga
Why Eli Lilly Stock Soared Today
Biogen's stunning win of FDA approval for aducanumab spurred investors' excitement about Lilly's prospects for its Alzheimer's disease candidate. 
Via The Motley Fool
Exposures Product Safety
Is Biogen a Buy?
Should you consider putting this volatile biotech in your portfolio? 
Via The Motley Fool
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Why Cassava Sciences Was Up 15% in May
Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval. 
Via The Motley Fool
Why Biogen's Stock Is Soaring Today
Biogen Inc. (NASDAQ: BIIB) shares are trading higher after the company was granted accelerated FDA approval for its ADUHELM Alzheimer's candidate. The accelerated approval has... 
Via Benzinga
Exposures Product Safety
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
There are better options for investors looking to profit from potential Alzheimer's disease treatments. 
Via The Motley Fool
Exposures Product Safety
BIIB Stock Alert: The Huge FDA News That Has Biogen Investors Smiling
Shares of BIIB stock were up to start the day on Monday after the FDA approved the firm's experimental drug to fight Alzheimer’s disease. 
Via InvestorPlace
Exposures Product Safety
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
Biogen's biologics license application for aducanumab, its investigational Alzheimer's treatment, received FDA approval under the accelerated approval pathway. 
Via Talk Markets
Exposures Product Safety
Biogen's Alzheimer's Disease Treatment Earns FDA Approval
Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories. 
Via The Motley Fool
Exposures Product Safety
Why Biogen Stock Is On Fire Today
The biotech's controversial Alzheimer's disease drug got a green light from the FDA. 
Via The Motley Fool
Exposures Product Safety
iShares Biotechnology Fund Spike Continues Rally, Nears Critical Resistance Level
The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) is making a big move higher, but there's a chance that the rally is about to end. The shares have reached a level that has... 
Via Benzinga
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line. FDA Okays Aducanumab:... 
Via Benzinga
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
Via Benzinga
Exposures Product Safety
Here's the Biggest Challenge Biogen Will Face if Its Alzheimer's Drug Is Approved
It will determine whether the drug becomes a blockbuster. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
What's In Store For Biogen Stock If Alzheimer's Drug Aducanumab Nabs FDA Nod?
Biogen stock rose Wednesday after an analyst suggested its controversial Alzheimer's treatment, aducanumab, could gain U.S. approval later this month. 
Via Investor's Business Daily
Exposures Product Safety
3 Biotech Stocks With Huge Catalysts in June
Binary events expected this month could have enormous implications for these drugmakers and their shareholders. 
Via The Motley Fool
Exposures Product Safety
Will This Big Decision Knock the Biogen Roller Coaster Off the Tracks?
A make-or-break moment approaches after years of dramatic swings in the stock. 
Via The Motley Fool
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study
Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing... 
Via Benzinga
Tesla And Comcast Lead The QQQ Higher Wednesday
U.S. indices had a mixed day of trading as traders and investors weigh Wednesday's earnings reports. Concerns over inflation and yields, a... 
Via Benzinga
'SPACs Attack' Recap: Looking Back At 3 SPAC Deals, SPAC Rumors And The Latest SPAC Headlines And Earnings
Last week featured three announced SPAC deals. The week also had earnings from several well-known former SPACs. Here is a look back at the week that was SPACs for deals, rumors... 
Via Benzinga
Annovis Bio Stock Rockets As Alzheimer's Drug Tops Biogen, Cassava Sciences
Annovis Bio said Friday its experimental Alzheimer's and Parkinson's treatment improved cognition in less than a month, leading ANVS stock to soar. 
Via Investor's Business Daily
Biogen, Ginkgo Bioworks In Gene Therapy Collaboration Worth $120M
Biogen Inc (NASDAQ: BIIB) and Ginkgo Bioworks have entered into a gene therapy collaboration to develop a next-generation adeno-associated virus (AAV)-... 
Via Benzinga
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.